Jumjum Pharma Sees Q2 Profit Rise
Jamjoom Pharma achieved a net profit of 137.63 million SAR during the second quarter of 2026, reflecting a 4.25% increase compared to the same period last year. This was supported by a 12.4% rise in revenues, reaching 445.31 million SAR, driven by higher sales volumes and successful product distribution. The demand for strategic products continued across Gulf markets, North Africa, and export markets. On a quarterly basis, profits declined by 18.18% compared to the first quarter of the same year, due to decreased revenues and increased promotional and distribution expenses. Despite this, the net profits for the first half of 2026 grew to 305.84 million SAR, an increase of 5.81%, with revenues rising by 8.54% to 926.7 million SAR. Additionally, shareholders' equity increased by 11.68% to reach 1.88 billion SAR, and earnings per share rose to 4.37 SAR.
Notice: This Is an AI-Generated Summary
Comments (0)